Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 3 1

Status

Terminated 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 3Recurrence 1Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 91Carboplatin 73Pemetrexed 58Nivolumab 50Docetaxel 47Cisplatin 47Paclitaxel 46Erlotinib Hydrochloride 37Radiotherapy 30Gemcitabine 27osimertinib 23Cetuximab 23Bevacizumab 21Ipilimumab 18Radiosurgery 14130-nm albumin-bound paclitaxel 14Taxes 13Gefitinib 13Cyclophosphamide 13avelumab 12atezolizumab 12durvalumab 11Albumin-Bound Paclitaxel 11cemiplimab 9Radiation 8Drug Therapy 8alectinib 7Injections 7Etoposide 7trametinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Non-Small-Cell Lung × rociletinib × Clear all
NCT01526928 2020-08-04

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

Clovis Oncology, Inc.

Phase 1/2 Terminated
612 enrolled 34 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Recurrence

NCT02630186 2019-07-05

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

Clovis Oncology, Inc.

Phase 1/2 Terminated
3 enrolled 8 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02580708 2018-10-02

Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

Clovis Oncology, Inc.

Phase 1/2 Terminated
7 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡